ITRM20070038A1 - Forme solubili di complessi di inclusione di inibitori dell istone deacetilasi e ciclodestrine loro processi di preparazione e impieghi in campo farmaceutico - Google Patents

Forme solubili di complessi di inclusione di inibitori dell istone deacetilasi e ciclodestrine loro processi di preparazione e impieghi in campo farmaceutico

Info

Publication number
ITRM20070038A1
ITRM20070038A1 IT000038A ITRM20070038A ITRM20070038A1 IT RM20070038 A1 ITRM20070038 A1 IT RM20070038A1 IT 000038 A IT000038 A IT 000038A IT RM20070038 A ITRM20070038 A IT RM20070038A IT RM20070038 A1 ITRM20070038 A1 IT RM20070038A1
Authority
IT
Italy
Prior art keywords
cyclodextrines
complexes
inhibitors
inclusion
histone deacetylase
Prior art date
Application number
IT000038A
Other languages
English (en)
Inventor
Rienzo Barbara Di
Antonello Mai
Original Assignee
Uni Degli Studi Di Roma La Sapienza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uni Degli Studi Di Roma La Sapienza filed Critical Uni Degli Studi Di Roma La Sapienza
Priority to IT000038A priority Critical patent/ITRM20070038A1/it
Priority to PCT/IT2008/000040 priority patent/WO2008090585A2/en
Priority to EP08720210.7A priority patent/EP2125023B1/en
Publication of ITRM20070038A1 publication Critical patent/ITRM20070038A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Nanotechnology (AREA)
  • Obesity (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IT000038A 2007-01-26 2007-01-26 Forme solubili di complessi di inclusione di inibitori dell istone deacetilasi e ciclodestrine loro processi di preparazione e impieghi in campo farmaceutico ITRM20070038A1 (it)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IT000038A ITRM20070038A1 (it) 2007-01-26 2007-01-26 Forme solubili di complessi di inclusione di inibitori dell istone deacetilasi e ciclodestrine loro processi di preparazione e impieghi in campo farmaceutico
PCT/IT2008/000040 WO2008090585A2 (en) 2007-01-26 2008-01-25 Soluble forms of inclusion complexes of histone deacetylase inhibitors and cyclodextrins, their preparation processes and uses in the pharmaceutical field
EP08720210.7A EP2125023B1 (en) 2007-01-26 2008-01-25 Soluble forms of inclusion complexes of histone deacetylase inhibitors and cyclodextrins, their preparation processes and uses in the pharmaceutical field

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000038A ITRM20070038A1 (it) 2007-01-26 2007-01-26 Forme solubili di complessi di inclusione di inibitori dell istone deacetilasi e ciclodestrine loro processi di preparazione e impieghi in campo farmaceutico

Publications (1)

Publication Number Publication Date
ITRM20070038A1 true ITRM20070038A1 (it) 2008-07-27

Family

ID=39567920

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000038A ITRM20070038A1 (it) 2007-01-26 2007-01-26 Forme solubili di complessi di inclusione di inibitori dell istone deacetilasi e ciclodestrine loro processi di preparazione e impieghi in campo farmaceutico

Country Status (3)

Country Link
EP (1) EP2125023B1 (it)
IT (1) ITRM20070038A1 (it)
WO (1) WO2008090585A2 (it)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120094971A1 (en) * 2008-09-03 2012-04-19 Repligen Corporation Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2970139T (pt) 2013-03-15 2018-08-01 Biomarin Pharm Inc Inibidores de hdac
EP3268358A1 (en) 2015-03-13 2018-01-17 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as hdac8 inhibitors
CN109310783B (zh) * 2016-03-31 2022-06-17 Mida科技有限公司 环糊精-帕比司他加合物
JP2019524879A (ja) * 2016-07-08 2019-09-05 ラネディス ファーマシューティカルズ リミテッド ライアビリティ カンパニー リソソーム蓄積症およびその他の単一遺伝子代謝疾患を処置および／または予防するための組成物および方法
US20180353446A1 (en) * 2017-06-07 2018-12-13 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing cancer
WO2019140417A1 (en) * 2018-01-15 2019-07-18 Daly Thomas P Aminopyridine based buffers with wide buffering ranges antibiotics and myelin disease therapy
CN108191749B (zh) * 2018-03-29 2021-04-13 上海赫腾精细化工有限公司 一种氟啶虫酰胺及其中间体4-三氟甲基烟酸的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56133236A (en) * 1980-03-22 1981-10-19 Kyowa Hakko Kogyo Co Ltd Sodium valproate clathrate
PH24782A (en) * 1985-10-24 1990-10-30 Sankyo Co Composition containing a penem or carbapenem antibiotic and the use of the same
YU43290B (en) * 1986-11-13 1989-06-30 Lek Tovarna Farmacevtskih Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine
US20050227915A1 (en) * 2001-05-02 2005-10-13 Steffan Joan S Methods and reagents for treating neurodegenerative diseases and motor deficit disorders
ATE542527T1 (de) * 2005-05-13 2012-02-15 Topotarget Uk Ltd Pharmazeutische formulierungen von hdac-hemmern
JP2007191398A (ja) * 2006-01-17 2007-08-02 Saisentan Igaku Kenkyusho:Kk 眼疾患治療剤
MX2008016125A (es) * 2006-06-26 2009-01-15 Novartis Ag Compuestos organicos.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120094971A1 (en) * 2008-09-03 2012-04-19 Repligen Corporation Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors
US9265734B2 (en) * 2008-09-03 2016-02-23 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
US9796664B2 (en) 2008-09-03 2017-10-24 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors

Also Published As

Publication number Publication date
WO2008090585A2 (en) 2008-07-31
EP2125023A2 (en) 2009-12-02
EP2125023B1 (en) 2013-10-16
WO2008090585A3 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
ITRM20070038A1 (it) Forme solubili di complessi di inclusione di inibitori dell istone deacetilasi e ciclodestrine loro processi di preparazione e impieghi in campo farmaceutico
IL274602A (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and use thereof in the preparation of medicaments for treating thrombocytopenia
CY2020037I1 (el) Παραγωγα 1-((5-ετεροαρυλθειαζολ-2-υλ) αμινοκαρβονυλ) πυρρολιδινο-2-καρβοξαμιδης ως αναστολεις φωσφατιδυλινοσιτολ 3-κινασης (ρι3κ) χρησιμα στη θεραπεια πολλαπλασιαστικων νοσων
IL255752B (en) Compounds, pharmaceutical compositions comprising the same and uses thereof for treating cardiovasclar disease, an inflammatory disease or cancer
IL209121A (en) Indazolil history, their medicinal preparations and their use in the preparation of medications for the treatment of inflammatory diseases
DK2172450T3 (da) Nye malonsyre- og sulfonamidderivater og farmaceutisk brug deraf.
NO2017002I2 (no) Kobicistat eller farmasøytisk akseptabelt salt derav og atazanavir eller farmasøytisk akseptabelt salt derav
IL203734A (en) Annotations of 6 - Triazolopyridazinesulfonyl Benzothiazole and Benzimidazole, a Method for their Preparation and Use as Medicines and Preparations
IL193230A (en) Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases
PT2641596T (pt) Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas
IL199187A (en) Indole history, pharmaceuticals including them and their use in the manufacture of medicines
SMT201400148B (it) Inibitori di jak2 e loro uso per il trattamento del cancro e di malattie mieloproliferative
SI2084151T1 (sl) Substituirani dihidropirazoloni za zdravljenje kardiovaskularnih in hematoloških bolezni
ZA200907761B (en) Subsituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials
DK3719018T3 (da) Purin og deazapurinderivater som farmaceutiske forbindelser
IL193467A0 (en) Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
IL206296A (en) History of aminopyrazole, and their medicinal products and their use in the preparation of drugs for the prevention and treatment of diseases
IL215074A0 (en) Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
WO2012020131A3 (en) Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2008106102A9 (en) Inhibitors of rtp801 and their use in disease treatment
ITPD20050242A1 (it) Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
IL203936A (en) HISTORY 4 - Pyrimidinsulfamide, Process for Preparation, Pharmaceutical Preparations Containing and Using it for Medication Preparation
DK2448940T3 (da) Derivater af 6,7,8,9 tetrahydro-pyrimido{1,2-a}pyrimidin-4-on, fremstilling og farmaceutisk anvendelse heraf
IL202307A (en) Multikinase inhibitors for use in the preparation of pharmaceuticals for the treatment of various cancers
IL194880A (en) Aminazole amine derivatives, their use in the treatment of diseases and pharmaceuticals containing them